Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2009-012855-90-CZ
EUCTR2009-012855-90-CZ
Active, not recruiting
Not Applicable

Randomised, placebo-controlled, double-blind, parallel-group, comparative study of two topical products for the treatment of psoriasis

Jelfa SA0 sitesJune 1, 2009
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsmild to moderate plaque psoriasis
DrugsDIPROSALIC

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
mild to moderate plaque psoriasis
Sponsor
Jelfa SA
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 1, 2009
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Jelfa SA

Eligibility Criteria

Inclusion Criteria

  • •clinical diagnosis of chronic, stable, mild to moderate plaque psoriasis affecting 5% to 20% of body surface area and PASI\<12
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •erythrodermic psoriasis
  • •guttate psoriasis
  • •pustular psoriasis
  • •application of topical corticosteroids 2 weeks before enrollment to the study
  • •systemic biologic therapy
  • •spontaneous improvement during recent 2 months
  • •rapidly deteriorating psoriasis in recent 2 months
  • •uncontrolled systemic disease
  • •known hypersensitivity to any test products
  • •pregnancy and breasfeeding

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Clinical study to investigate the efficacy, safety and tolerability of Naloxone in patients with opioid induced constipatio
EUCTR2017-000657-39-DEDevelco Pharma Schweiz AG1,492
Active, not recruiting
Phase 1
Clinical study to investigate the efficacy, safety and tolerability of Naloxone in patients with opioid induced constipation.
EUCTR2017-000657-39-PTDevelco Pharma Schweiz AG563
Active, not recruiting
Not Applicable
Clinical study to investigate the efficacy, safety and tolerability of Naloxone in patients with opioid induced constipation.Opioid-induced bowel dysfunction (OBD) involves not only constipation, but also a constellation of symptoms including incomplete evacuation, bloating, abdominal distension, and increased gastric reflux.Constipation is an almost inevitable consequence of opioid use in malignant and non-malignant disease states, and one of the side effects of opioids to which few patients develop tolerance.MedDRA version: 16.1Level: LLTClassification code 10071128Term: Opioid induced constipationSystem Organ Class: 100000004856Therapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]
EUCTR2012-004311-31-PLDevelco Pharma Schweiz AG306
Active, not recruiting
Not Applicable
Randomised, double-blind, placebo-controlled, parallel group trial to confirm the efficacy, safety and tolerability of Ginkgo biloba Special Extract EGb 761® in patients suffering from Mild Mental Impairment (MMI) - NA
EUCTR2005-005765-11-EEDr. Willmar Schwabe GmbH & Co. KG300
Active, not recruiting
Phase 1
Clinical study to investigate the efficacy, safety and tolerability of Naloxone in patients with opioid induced constipatioOpioid induced constipationMedDRA version: 20.0Level: LLTClassification code 10071128Term: Opioid induced constipationSystem Organ Class: 100000004856Therapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]
EUCTR2017-000657-39-GBDevelco Pharma Schweiz AG563